+

WO2003034069A3 - Tcmp 03 protein for use in cancer therapy - Google Patents

Tcmp 03 protein for use in cancer therapy Download PDF

Info

Publication number
WO2003034069A3
WO2003034069A3 PCT/GB2002/004740 GB0204740W WO03034069A3 WO 2003034069 A3 WO2003034069 A3 WO 2003034069A3 GB 0204740 W GB0204740 W GB 0204740W WO 03034069 A3 WO03034069 A3 WO 03034069A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
tcmp
cancer therapy
compositions
cancer
Prior art date
Application number
PCT/GB2002/004740
Other languages
French (fr)
Other versions
WO2003034069A2 (en
Inventor
Jonathan Alexander Terrett
Original Assignee
Oxford Glycosciences Uk Ltd
Jonathan Alexander Terrett
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Glycosciences Uk Ltd, Jonathan Alexander Terrett filed Critical Oxford Glycosciences Uk Ltd
Priority to AU2002336185A priority Critical patent/AU2002336185A1/en
Publication of WO2003034069A2 publication Critical patent/WO2003034069A2/en
Publication of WO2003034069A3 publication Critical patent/WO2003034069A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a protein, designated TCMP 03, and to compositions comprising the protein, including vaccines, antibodies that are immunospecific for the protein, and to agents that modulate the expression or activity of the protein. The use of these compositions in the diagnosis, screening and treatment of cancer is also provided.
PCT/GB2002/004740 2001-10-18 2002-10-18 Tcmp 03 protein for use in cancer therapy WO2003034069A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002336185A AU2002336185A1 (en) 2001-10-18 2002-10-18 Tcmp 03 protein for use in cancer therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0125072.9 2001-10-18
GB0125072A GB0125072D0 (en) 2001-10-18 2001-10-18 Protein

Publications (2)

Publication Number Publication Date
WO2003034069A2 WO2003034069A2 (en) 2003-04-24
WO2003034069A3 true WO2003034069A3 (en) 2003-10-16

Family

ID=9924117

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/004740 WO2003034069A2 (en) 2001-10-18 2002-10-18 Tcmp 03 protein for use in cancer therapy

Country Status (3)

Country Link
AU (1) AU2002336185A1 (en)
GB (1) GB0125072D0 (en)
WO (1) WO2003034069A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005969A1 (en) * 1996-08-05 1998-02-12 New York University Mammalian and human fxi-t1
WO2001062784A2 (en) * 2000-02-25 2001-08-30 Oxford Glycosciences (Uk) Ltd. Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005969A1 (en) * 1996-08-05 1998-02-12 New York University Mammalian and human fxi-t1
WO2001062784A2 (en) * 2000-02-25 2001-08-30 Oxford Glycosciences (Uk) Ltd. Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 14 January 2000 (2000-01-14), XP002244416, retrieved from EBI Database accession no. AF090927 *
DATABASE GENBANK [online] 31 August 2001 (2001-08-31), XP002244417, retrieved from EMBL Database accession no. BE068786 *
EMMANUEL DIAS NETO ET AL: "SHOTGUN SEQUENCING OF THE HUMAN TRANSCRIPTOME WITH ORF EXPRESSED SEQUENCE TAGS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 97, no. 7, be068786, 28 March 2000 (2000-03-28), pages 3491 - 3496, XP000996193, ISSN: 0027-8424, Retrieved from the Internet <URL:EBI> *

Also Published As

Publication number Publication date
GB0125072D0 (en) 2001-12-12
WO2003034069A2 (en) 2003-04-24
AU2002336185A1 (en) 2003-04-28

Similar Documents

Publication Publication Date Title
WO2002074337A8 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
WO2003083485A3 (en) Protein for use in hypoxia related conditions
HK1145692A1 (en) Specific binding agents of human angiopoietin-2 -2
WO1997017446A3 (en) HUMANIZED ANTIBODIES TO HUMAN gp39, COMPOSITIONS CONTAINING AND THERAPEUTIC USE THEREOF
NZ332720A (en) Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia
EP0671920A4 (en) An anti-idiotypic antibody and its use in diagnosis and in therapy in hiv-related disease.
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
WO2003087831A3 (en) Proteins involved in breast cancer
IL110464A0 (en) Novel proteins for the diagnosis, imaging, and therapy of human cancer
MXPA03008739A (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours.
AU2002226690A1 (en) Drugs for the diagnosis of tissue-reproductive activity or the treatment of proliferative diseases
ZA982968B (en) Compositions and methods for the treatment and diagnosis of breast cancer
EP1706423B8 (en) Therapeutic and diagnostic anti-hsp 70 antibodies
WO2002046221A3 (en) Human protein differentially expressed in alzheimer&#39;s disease&#39;s brain
IL171384A (en) Use of slurp-1 in the preparation of medicaments for the treatment of neurological disorders
GB0004576D0 (en) Proteins
EP0967276A3 (en) Anti-tumor agent comprising salmosin
WO2003055440A3 (en) Compositions and methods for the treatement of immune related diseases
WO2003087840A3 (en) Protein involved in cancer
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
WO2003034069A3 (en) Tcmp 03 protein for use in cancer therapy
AU2003228339A1 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
WO1999050671A3 (en) Toso as a target for drug screening
DE69813354D1 (en) Agents for the treatment of heart diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载